Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of maternal pertussis vaccination on infant antibody responses
2019-001986-34Phase 4Completed
- Sponsor
- Turku University Hospital
- Start
- Aug 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of acellular pertussis vaccine in pertussis (2 arms), sponsored by Turku University Hospital. Primary endpoint: Primary: PT-specific IgG antibody GMC at 6 months in infants. Started Aug 2019; status: completed.
02
Drugs
acellular pertussis vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on 2019-001986-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001986-34.